Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Harman

Neurological Surgery Charleston, WV Doctor of Osteopathy

NPI 1033477278 CMS profile 1382261

415 Morris St Ste 400, Charleston, WV 25301

Open in the dashboard

General payments

$28,008

354 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Harman of Charleston, WV is reported in the CMS Open Payments database as having received $28,008 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,769 19
2024 General $4,162 56
2023 General $5,216 56
2022 General $2,433 45
2021 General $2,345 43
2020 General $5,006 57
2019 General $7,077 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Harman
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to James Harman were reported at $1,769. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year James Harman Neurological Surgery median Middle half National median
2019 $7,077 $582 $138–$3,006 $163
2020 $5,006 $294 $76–$2,174 $114
2021 $2,345 $387 $105–$2,432 $132
2022 $2,433 $542 $139–$2,989 $149
2023 $5,216 $534 $145–$2,697 $160
2024 $4,162 $574 $155–$3,046 $164
2025 $1,769 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SI-BONE, Inc. $8,471 98 payments
  2. Medtronic, Inc. $4,137 50 payments
  3. Medtronic USA, Inc. $3,668 31 payments
  4. Abbott Laboratories $3,602 69 payments
  5. MicroVention, Inc. $2,307 11 payments
  6. Penumbra, Inc. $2,257 41 payments
  7. Boston Scientific Corporation $967 9 payments
  8. DePuy Synthes Sales Inc. $842 11 payments
  9. Nevro Corp. $668 15 payments
  10. Globus Medical, Inc. $318 3 payments
  11. Other $771 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $19,201 331 payments
  2. Travel and Lodging $8,534 21 payments
  3. Education $273 2 payments
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT $3,370 52 payments
  2. IFUSE IMPLANT SYSTEM $2,535 5 payments
  3. MazorX - Renaissance $2,214 8 payments
  4. WEB $2,162 9 payments
  5. STEALTHSTATION S8 PLATFORM $2,114 10 payments
  6. Proclaim Family of SCS IPGs $1,369 23 payments
  7. Pipeline Flow Diversion $1,348 24 payments
  8. PROCLAIM $1,213 21 payments
  9. Penumbra System $817 19 payments
  10. Pipeline Flow Diversion $475 5 payments
  11. Other $9,139 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

344

Median for Neurosurgery: 83

Drug cost

$1,982

Median for Neurosurgery: $872

Branded share of claims

31.1%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cyclobenzaprine Hcl Generic 103 $424
Tizanidine Hcl Generic 19 $333
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 36 $191
Clopidogrel Clopidogrel Bisulfate Brand 38 $170
Methylprednisolone Generic 24 $159
Diclofenac Sodium Generic 18 $157
Oxycodone Hcl Generic 29 $127
Meclizine Hcl Generic 11 $117
Acetaminophen-Codeine Acetaminophen With Codeine Brand 15 $97
Gabapentin Generic 20 $91

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$96,267

Medicare's payments for the services billed

Medicare patients

198

Average age 73

Services billed

460

102 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 49%
Diabetes 42%
Depression 35%
Chronic kidney disease 33%
COPD 29%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record